Table 2.

UL97 Genotyping Follow-up on Patients With CMV Clearance and Recurrence While on Maribavir

	Both Trials	Trial 202				Trial 203
Characteristic	All Doses	All Doses	400 mg	800 mg	1200 mg	All Doses	400 mg	800 mg
No. of patients with recurrence on maribavir after clearance	29	25	6	9	10	4	2	2
No. of patients with UL97 follow-up genotyping data	23	19	5	9	5	4	2	2
Median treatment duration, d	95	111	95	160	76	70	74	57
Median starting CMV load, copies/mL	10 000	10 000	10 000	10 000	20 000	5500	5500	6500
Median study day at follow-up  genotyping	84	86	106	87	83	71	75	62
Study day range at follow-up	52–169	70–169	85–122	71–169	70–161	52–80	69–80	52–72
UL97 mutation detected, No.a
T409M	14 (61%)	10	2	5	3b	4	2	2
H411Y	3 (13%)	3	2	1	0	0	0	0
C480F	6 (26%)	6	0	3	3b	0	0	0
T409M, H411Y, or C480F	22 (96%)	18	4	9	5	4	2	2

Abbreviations: CMV, cytomegalovirus.

^aPercentages based on number with available UL97 genotyping data.

^bOne patient had UL97 C480F and T409M detected.